KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Receivables (2016 - 2025)

Gilead Sciences (GILD) has disclosed Receivables for 17 consecutive years, with $5.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables fell 0.96% year-over-year to $5.5 billion, compared with a TTM value of $5.5 billion through Dec 2025, down 0.96%, and an annual FY2025 reading of $5.5 billion, up 17.99% over the prior year.
  • Receivables was $5.5 billion for Q4 2025 at Gilead Sciences, down from $5.8 billion in the prior quarter.
  • Across five years, Receivables topped out at $5.8 billion in Q3 2025 and bottomed at $3.9 billion in Q1 2021.
  • Average Receivables over 5 years is $5.0 billion, with a median of $5.0 billion recorded in 2022.
  • The sharpest move saw Receivables soared 52.35% in 2021, then fell 15.96% in 2022.
  • Year by year, Receivables stood at $4.7 billion in 2021, then increased by 6.02% to $4.9 billion in 2022, then fell by 3.46% to $4.8 billion in 2023, then increased by 17.14% to $5.6 billion in 2024, then decreased by 0.96% to $5.5 billion in 2025.
  • Business Quant data shows Receivables for GILD at $5.5 billion in Q4 2025, $5.8 billion in Q3 2025, and $5.1 billion in Q2 2025.